Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
Paramyxoviruses such as human parainfluenza viruses that bear inserts encoding protective antigens of heterologous viruses can induce an effective immunity against the heterologous viruses in experimental animals. However, vectors based on common human pathogens would be expected to be restricted in replication in the adult human population due to high seroprevalence, an effect that would reduce vector immunogenicity. To address this issue, we evaluated Newcastle disease virus (NDV), an avian paramyxovirus that is serotypically distinct from common human pathogens, as a vaccine vector. Two strains were evaluated: the attenuated vaccine strain LaSota (NDV-LS) that replicates mostly in the chicken respiratory tract and the Beaudette C (NDV-BC) strain of intermediate virulence that produces mild systemic infection in chickens. A recombinant version of each virus was modified by the insertion, between the P and M genes, of a gene cassette encoding the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neuraminidase (HN) protein, a test antigen with considerable historic data. The recombinant viruses were administered to African green monkeys (NDV-BC and NDV-LS) and rhesus monkeys (NDV-BC only) by combined intranasal and intratracheal routes at a dose of 10(6.5) PFU per site, with a second equivalent dose administered 28 days later. Little or no virus shedding was detected in nose-throat swabs or tracheal lavages following immunization with either strain. In a separate experiment, direct examination of lung tissue confirmed a highly attenuated, restricted pattern of replication by parental NDV-BC. The serum antibody response to the foreign HN protein induced by the first immunization with either NDV vector was somewhat less than that observed following a wild-type HPIV3 infection; however, the titer following the second dose exceeded that observed with HPIV3 infection, even though HPIV3 replicates much more efficiently than NDV in these animals. NDV appears to be a promising vector for the development of vaccines for humans; one application would be in controlling localized outbreaks of emerging pathogens.
Bukreyev
Alexander
A
LID, NIAID, NIH, 50 South Dr., Rm. 6505, Bethesda, MD 20892-8007, USA. abukreyev@niaid.nih.gov
Huang
Zhuhui
Z
Yang
Lijuan
L
Elankumaran
Subbiah
S
St Claire
Marisa
M
Murphy
Brian R
BR
Samal
Siba K
SK
Collins
Peter L
PL
D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D001483:Base Sequence; D002522:Chlorocebus aethiops / Q000097:blood / Q000276:immunology; D015707:HN Protein / Q000235:genetics / Q000276:immunology*; D007117:Immunization, Secondary; D008253:Macaca mulatta / Q000097:blood / Q000276:immunology; D008969:Molecular Sequence Data; D009297:Nasal Mucosa / Q000821:virology; D009522:Newcastle disease virus / Q000276:immunology* / Q000302:isolation & purification; D010224:Parainfluenza Virus 3, Human / Q000235:genetics / Q000276:immunology*; D010614:Pharynx / Q000821:virology; D016865:Reassortant Viruses / Q000276:immunology* / Q000302:isolation & purification; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D015707:HN Protein; D014614:Vaccines, Synthetic; D014765:Viral Vaccines